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INTRODUCTION 
Acetylcholine (ACh), an important neurotransmitter in the central and 
peripheral nervous systems, is inactivated by the enzyme acetylcholines-
terase (AChE). The role of AChE within the cholinergic system is, 
therefore, important and inhibition of this enzyme has profound 
pharmacological consequences. Organophosphates are irreversible inhibitors 
of AChE, and thus, in their presence ACh persists at the cleft of 
cholinergic synapses causing a dysfunction of neural pathways utilizing ACh 
as a transmitter (Taylor, 1980). 
Choline, one of the products of ACh hydrolysis, is required for 
synthesis of ACh and reenters the presynaptic cell by an active high 
affinity sodium dependent choline transport system (Yamamura and Snyder, 
1973). Hemicholinium-3 (HC-3) is a potent antagonist of this active 
transport, preventing ACh synthesis, and thus depleting presynaptic 
terminals of ACh (Mcintosh and Collier, 1976). This action makes HC-3 a 
potential physiological antagonist to organophosphates. 
While the pharmacological actions of HC-3 have been documented (for 
review see Bowman and Marshall, 1972), the bis-quaternary ammonium 
structure of this compound (and its consequent inability to cross the blood 
brain barrier) has limited its study as a putative antagonist to 
organophosphates, which do cross the blood brain barrier and have central 
effects such as respiratory depression. Harris, Stitcher and Heyl (1982 ) , 
however, demonstrated that intraventricular administration of HC-3 protects 
against lethal doses of soman in both rats and rabbits, and proposed that 
the HC-3 effect was due to inhibition of ACh synthesis. 
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Since tertiary compounds are known to have better penetration through 
the blood brain barrier than quaternary compounds, a tertiary hemicholinium 
may prove useful as an antagonist to organophosphate poisoning. As no 
tertiary hemicholinium is at present commercially available, part of this 
thesis describes the synthesis of one such compound and its subsequent 
pharmacological evaluation. 
One preparation that is suitable for pharmacological investigations 
into both organophosphates and hemicholiniums is the rat isolated phrenic 
nerve-diaphragm, which is a proven model for neuromuscular transmission 
(Bulbring, 1946). Bowman, Hemsworth and Rand (1967) demonstrated the 
presynaptic blockade of muscle twitch amplitude in this preparation and the 
cat anterior tibialis muscle by HC-3, and also showed antagonism of this 
blockade by choline. 
Organophosphates (e.g.diisopropylphosphoroflouridate or DFP ) have been 
shown to cause reversible depression of 60 Hz tetanic contrac tion 
amplitude, and enhance 0.2 Hz single twitch amplitude of the rat isolated 
phrenic nerve-diaphragm (Van der Meer and Meeter, 1956a,b), actions that 
have been correlated with a decrease in cholinesterase activity (Barstad, 
1960). French, Wetherell and White (1979) using the same preparati on 
showed that soman causes an irreversible block of 60 Hz tetanic contraction 
amplitude, an effect antagonized by pretreatment with pyridostigmine. 
This thesis examines the pharmacological properties of HC-3 on the rat 
isolated phrenic nerve-diaphragm, and studies the antagonism by HC-3 of 
organophosphate (DFP and soman) induced depression of tetanic contraction 
amplitude and post-tetanic potentiation. 
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LITERATURE REVIEW 
Pharmacology of the Hemicholiniums 
Acetylcholine (ACh) is utilized as a neurotransmitter at several sites 
in the peripheral nervous system including the somatic neuromuscular 
junction, autonomic ganglia, and the parasympathetic neuroeffector 
junction. In the central nervous system, ACh is a known transmitter at 
spinal motoneuron axon collateral-Renshaw cells, and is a putative 
transmitter in several regions of the brain (for review see Cooper, Bloom 
and Roth, 1978). 
ACh is synthesized at presynaptic terminals by choline acetyltrans-
ferase (CAT) and packaged into synaptic vesicles which fuse with the 
presynaptic membrane to cause release when the membrane is depolarized by a 
presynaptic action potential. The ACh transverses the synapse to bind with 
nicotinic receptors (ganglia, neuromuscular junction ) or muscarinic 
receptors (parasympathetic neuroeffector junction). Inactivation of ACh is 
carried out by acetylcholinesterase (AChE), which hydrolyses the 
neurotransmitter to choline and acetate. Choline is actively taken up by 
the presynaptic terminal for resynthesis of ACh ( for review of above see 
Kandel and Schwartz, 1981). 
Several classes of drugs have been employed both clinicall y and 
experimentally to interfere with cholinergic transmission. Of these 
classes, neuromuscular blockers, ganglionic blockers, antimuscarinics, 
anticholinesterase agents, and inhibitors of ACh release had all been 
described by 1950 (Taylor, 1980). Until the discovery of hemicholiniums, 
no known drugs existed that could inhibit ACh synthesis per se. 
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The pharmacological evaluation of a series of a ,a 'quaternary ammonium 
salts synthesized from 4, 41 -bisacetophenone revealed three distinctly 
different mechanisms of action, dependent on the derivation of the salt 
(Long and Schueler, 1954; Schueler, 1955). Products derived f rom 
heterocyclic tertiary amines, were found to be potent anticholinesterase 
agents and were antagonized by atropine. Products derived from simpl e 
trialkyl tertiary amines exhibited the properties of rapidly acting 
neuromuscular blocking agents such as curare, and were antagonized by 
neostigmine and edrophonium. The third group of compounds derived from 
ethanol tertiary amines caused a delayed toxicity after intraperitoneal 
(i.p . ) administration to mice, death occurring due to respiratory 
paralysis. This effect was antagonized by choline chloride. Compound 
number 3 in the series (a ,a 'dimethyl ethanolamino 4, 41 - bisacetophenone), 
was found to undergo spontaneous hemiacetal formation, and was thus named 
hemicholinium- 3 or HC-3 (Schueler, 1955); the pharmacology of t his 
compound, which was found to be the most toxic of the third group, has been 
studied in detail. 
Schueler (1955) studied the toxicity of HC-3 in dogs, rabbits, guinea 
pigs, rats and mice and found that in all cases death resulted from a 
gradually-developing respiratory failure. Unlike most drugs, the toxic 
dose on a body-weight basis was greater , and the time to death lo nger, i n 
larger animals. Schueler also found that in doses 100 times t he LD
50 
an 
immediate neuromuscular paralysis could be induced. The delayed 
respiratory failure produced by HC-3 was poorl y antagonized by 
anticholinesterase drugs, but pretreatment with cho l ine protected against 
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the toxic effects (Schueler, 1955; Giovinco, 1957). Kase and Borison 
(1958) analyzed the effects of HC-3 by means of electrical stimulation of 
transections of the lower brain stem in unanaesthetized, pentobarbital 
anaesthetized and decerebrate cats. From their studies they concluded that 
the HC-3 respiratory paralyzant action was mainly due to depression of the 
respiratory regulatory mechanism, an action they thought too k precedence 
over peripheral neuromuscular blockade. However, Longo (1959 ) found li ttle 
change in phrenic action potentials recorded in cats and rabbits during 
full respiratory paralysis, a result more consistent with the known 
inability of quaternary ammonium compounds to penetrate the blood brain 
barrier. 
Long and Schueler (1954) reported that HC-3 had no effect on the cat 
sciatic nerve-gastrocnemius muscle preparation when the nerve was 
stimulated at 0.1 Hz, however, 40-70 minutes after i.v. injection of HC-3, 
1.0 Hz stimulation of the rabbit sciatic nerve resulted in a bloc kade of 
gastrocnemius muscle contraction (Reitzel and Long, 1959a ) . In addition it 
was found that HC-3 blockade of muscle contraction could be antagonized by 
choline chloride, or by removing the stimulus for ten to fifteen minutes 
(Reitzel and Long, 1959a ) . 
Comparing a series of choline esters, Reitzel and Long (1959a ) also 
concluded that the ~tructure of choline was specific for antagonism of 
HC-3. Several esters of choline, including ACh were also effective 
antagonists but this was shown to be due to the choline liberated by their 
rapid hydrolysis, since the antagonism was prevented by tetraethylpyro-
phosphate (TEPP), an anticholinesterase. The specific antagonistic action 
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of choline and the frequency dependent blockade of muscle contraction 
suggested that HC-3 interferes with choline metabolism and thus causes a 
decreased synthesis of ACh. 
Mcintosh, Birks and Sastry (1956) added HC-3 to eserinized plasma 
perfusing the cats superior cervical ganglion, and found that after several 
minutes time lag, the rate of ACh release declined rapidly during 
repetitive stimulation. In addition, HC-3 diminished the ra te of synthesis 
of ACh in minced mouse brain by 75%, but this action was muc h wea ker in 
acetone-dried rat brain powder. As acetone destroys the integrity of 
membranes, Mcintosh, Birks and Sastry (1956) proposed that HC-3 competes 
with choline for transport into nerve terminals by a specific carrier 
system. Gardiner (1961) confirmed this proposal when he found that HC-3 
inhibiterl ACh synthesis in guinea pig brain homogenates, but had no effect 
on homogenates pretreated with ether, a procedure that disrupts membra nes 
surrounding the CAT enzyme (Hebb and Smallman, 1956 ) . 
The inhibition by HC-3 of active choline secretory systems was 
demonstrated in avian kidney tubules (Mcintosh, Birks and Sastry, 1956); 
and HC-3 was also shown to inhibit active uptake of choline by isolated 
perfused hearts (Buterbaugh and Spratt, 1968), and erythrocytes (Martin , 
1969). It was not until the development of techniques utilizing isolated 
mammalian brain synaptosomes, that Marchbanks (1968) and Diamond and 
Kennedy (1969) demonstrated choline uptake by nervous tissue. However, in 
these investigations, very little synthesis of ACh was foJnd to be 
associated with choline transported into synaptosomes. The reason for this 
was shown by Haga (1971) to be due to the fact that in the early 
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experiments relatively high concentrations of choline were used. When 
synaptosomes were exposed to low levels of choline, Haga (1971 ) observed 
that 50% of the radioactive choJine taken up was converted to ACh. Based 
on this observation , Haga (1971) predicted the presence of two separate 
choline transport systems, one of which had a high affinity for choline. 
Thereafter, Yamamura and Snyder (1973 ) and Haga and No da (1973) 
demonstrated by kinetic analysis the presence of two choline transport 
systems in isolated rat brain synaptosomes. One was a l ow affinity system 
(Km = 90 µM) which was not energy-dependent, was not associa ted with an 
efficient synthesis of ACh, and did not parallel the regional distri bution 
of CAT in the brain. Yamamura and Snyder (1973 ) showed that HC- 3 was 
relatively ineffective in inhibiting the low affinity system, as at 100 µM 
concentration, it caused no greater reduction of choline synaptosomal 
accumulation than did neostigmine or atropine. 
The other transport system had a high affinity for choline (Km = 4-8 
µM), was highly sodium dependent, associated with an efficient syn t hesis of 
ACh, and had a regional distribution in brain which paralleled that of CAT. 
The dependency on sodium is strict as caesium and lithium do not affect 
choline uptake. Transport is optimal at low concentrations of potassium, 
and the system is also chloride dependent (Simon and Ku ha r , 1976) . 
Yamamura and Snyder (1973) also demonstrated that HC-3 (100 µM) reduced 
cholJne synaptosomal accumulation to 31% of control, HC-3 bei ng t he most 
active drug tested at this concentration. Other potent inhibitors of the 
system are bretylium and ACh (Haga and Noda, 1973 ) . The potency of HC-3 
and other bisalkonium compounds was confirmed by Barker and Mittag (1975 ) , 
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who also found that potency in high affinity choline uptake inhibition was 
proportional to potency for ACh depletion . The high affinity choline 
uptake system is now regarded as the rate-limiting step in ACh synthesis . 
The exact biochemical mechanism by which HC-3 inhibits ACh synthesis 
remains controversial, and the assumption that its presynaptic action is 
solely at the level of the plasma membrane may be an oversimplification . 
The effects of HC-3 on ACh turnover in muscles and ganglia are only slowly 
reversed by removing the drug from the medium (Cheymol , Bourillet and 
Ogura, 1962; Matthews, 1966). This is in contrast to the effects of 
postsynaptic blockers, which quickly dissappear when the medium is made 
drug-free . Some authors (Mcintosh, 1961; Rodriguez de Lores Amaiz, Zieher 
and DeRobertis, 1970) have proposed that in addition to choline transport 
inhibition, HC-3 or its acetyl ester, may be stored and released as a false 
transmitter . Intracellular uptake of HC-3 in the rat striatum (Csilli k, 
Haarstad and Knyihar, 1970 ) and canine caudate nucleus and hippocampus 
(Se llinger et al., 1969) has been demonstrated . However , Collier (1973) 
using the ca t superior cervical ganglion preparation showed that although 
HC-3 accumulated intracellularly, it was not by the same mechanism as 
choline. Also, HC-3 did not replace ACh stoichiometrically, and could not 
be released by nerve stimulation. 
In addition, although several studies have shown that HC- 3 
competitively inhibits CAT, and is itself acetylated ..!.!! vitro (Mann and 
Hebb, 1975; Bradshaw and Hemsworth, 1976) this has never been successfull y 
demonstrated..!.!! vivo. As it is now co nsidered that high affinity choline 
transport and ACh synthesis are ki neticall y coupled (Marchbanks and 
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Kessler, 1982 ) , i t is probable that HC-3 acts primari ly by inhi biting 
choline transport (for review see Jope, 1979 ) . One possibility that 
remains is that HC-3 may interfere with the transfer of ACh from the 
cytosol to synaptic vesicles, a process about which almost nothing is 
known. 
The cholinergic actions of HC- 3 are not entirel y prejuncti onal. In 
large doses it produces an immediate respiratory para lysis which di ffe rs 
from the delayed effect of small doses in that i t may be reversed by 
anti cholinesterase drugs, but not by choline (Schueler, 1955 ) . Thi s 
suggests, as might be expected from its chemi cal structure, that large 
doses exert a postjunctional curare-like bloc k at the neuromuscul ar 
junction, and this has been confirmed in exper iments on isolated nerve 
muscle preparations (Reitzel and Long, 1959a; Bowman and Rand, 1961 ) . 
The postjunctional blocking act i on may contribute to a smal l extent to 
the paralysis produced by small doses, since, even before any transmi ss ion 
failure becomes evident (as judged by the amplitude of muscle t wi tch ) some 
depression of responses to ACh and r elated agonists is observed (Bove and 
Haarstad, 1979 ) . Any postjunctional blocking ac tion must become relat ively 
more important as transmitter outpu t fails and norma l safety marg i ns i n 
transmitter release become diminished (Paton and Waud, 1967 ) . 
In the sympathetic ganglia, the interonium distance in HC-3 is t oo 
great for effective combination with the postsynaptic receptors, and thus 
at this site, in contrast to the neuromuscular j unct i on, transmiss i on 
failure is almost exclusive ly due to presynaptic mechanisms (Bhatnager, Lam 
and McColl, 1965 ). In smooth muscle HC- 3 has been shown to possess some 
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atropine- like action but this to too weak to contribute much to 
transmission failure (Bertolini, Greggia and Ferrari, 1967 ) . 
Intracellular recording techniques at the neuromuscular junction have 
confirmed t hat HC-3 possesses a postjunctional action. Martin and Orkand 
(1961a , b), using isolated frog extensor digitalis muscles, found that HC-3 
decreased the amplitude of end plate potentials in response to nerve 
stimulation or iontophoretically applied ACh. This postsynaptic action was 
not antagonized by choline. Thies and Broo ks (1961 ) confirmed this wor k 
using guinea pig serratus nerve-muscle preparations finding that the 
postsynaptic action of HC-3 is antagonized by eserine, but not by choline. 
In addition, the postsynaptic blockade of neuromuscular transmission by HC-
3, unlike presynaptic blockade, is both immediate in onset, and is not 
dependent on frequency of stimulation. 
The pharmacological effects of HC-3 have been studied in both 
peripheral and central cholinergic sites. In the periphery, HC-3 has been 
found to produce neuromuscular blockade in sciatic nerve-gastrocnemi us 
muscle preparations of dogs, rabbits, and chickens (Reitzel and Long, 
1959a), superior cervical ganglion-nictitating membrane of cats (Wilson and 
Long, 1959 ) , and anterior tibialis-sciatic nerve of cats (Evans and Wilson, 
1964). 
In all of the above preparations, HC-3 at low doses is ineffective at 
stimulation freque ncies below 1 Hz, and as stimulus frequency is increased, 
so the drug becomes more effective. At stimulation frequencies of 1 Hz or 
more a slowly developing decrease in muscle twitch amplitude is seen 
(Bowman and Marshall, 1972). Tetanic stimulation causes poorly sustained 
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tension, followed by little post-tetanic potentiation. Another preparation 
used for studying HC-3 and neuromuscular transmission is the rat isolated 
phrenic nerve-diaphragm, because of its relative insensitivity to 
postsynaptic effects (Bowman, Hemsworth and Rand, 1967). Recording 
intracellularly, Elmquist and Quastel (1965) demonstrated that at low 
concentrations, HC-3 caused a progressive decline in the size of miniature 
end plate potentials (m.e.p.p.s) and in the quantal components of the end 
plate potential as transmitter was released. When used as an isolated 
tissue preparation, the rat phrenic nerve diaphragm shows properties 
similar to other nerve-muscle preparations previously mentioned, except 
that choline is a poor antagonist in the presence of HC-3 (Rand and Chang, 
1960). 
Other peripheral sites used to study HC-3 have included autonomic 
neuroeffector junctions. At these sites HC-~ acts i n a similar fashion as 
is seen at the somatic neuromuscular junction (Everett, 1968; Vanov, 1965; 
Rand and Ridehalgh, 1965; Appel and Vincenzi, 1970; Lindmar et al., 1980). 
In addition, inhibition of ACh synthesis by HC-3 has been demonstrated at 
sympathetic ganglia (Birks and Mcintosh, 1961 ) , and also at the 
sympathetically innervated guinea pig vas deferens (Chang and Rand, 1960 ) . 
The central actions of HC-3 after intraventricular (ivt) injection 
have also been studied. HC-3 produces a brief period of catatonia after 
ivt injection into conscious animals (Slater, 1968), followed occasionally 
by seizures (Shellenberger and Domino, 1967; Slater, 1968). Reduction of 
brain ACh levels by HC-3 has been correlated wi th an increased number of 
median trials to acquire a conditioned avoidance response in rats (Russel 
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and Macri, 1978). It has also been reported that HC-3 causes a behavioral 
response in rats similar to, but less severe than, that caused by septal 
lesions, the intraventricular dose being correlated to the intensity of the 
response (Freeman et a 1., 1979). 
In addition to whole brain studies, the levels of ACh after HC-3 
administration have been studied in areas of the brain believed to have a 
cholinergic component. HC-3 has been found to reduce ACh levels in the 
caudate nucleus (Hebb et al., 1964), cerebral hemispheres, midbrain, pons 
(Slater, 1969), cerebral slices (Richter, 1976), striatum, cortex, 
cerebellum and hippocampus (Freeman et al., 1979). In all of the above 
cases, the effects of HC-3 were antagonized by administration of choline 
chloride. HC-3 does not antagonize the active transport of choline through 
the blood-brain barrier, however, and it is presumed that this transport 
occurs via a different mechanism (Ross and Jenden, 1973). 
Radioactive 14c-HC-3 has also been used as a tool to locate sites of 
ACh synthesis in canine caudate nucleus and hippocampus (Sellinger et al., 
1969 ) , and in whole rat brain (Csillik, Haarstad and Knyihar, 1970), both 
utilizing autoradiographic techniques. In spontaneously hypertensive rats, 
intracerebroventricular injection of HC-3 has been shown to lower blood 
pressure (Brezenhoff and Caputi, 1980); and ivt administration of HC-3 
produces a dose-dependent hypothermia in rats (Li n, Wang and Chandra, 
1980). 
HC-3 antagonizes the tremor produced by eserine in rats (Slater and 
Rodgers, 1968) and prevents the rise in brain ACh produced by this 
compound. Choline restores the tremors by reversing the inhibition of ACh 
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synthesis (Slater and Rodgers, 1968). In rats intoxicated with the 
organophosphorous anticholinesterase agent soman, intraventricular 
administration of HC-3 prevented a soman-induced rise in brain ACh levels, 
and protected against soman toxicity (Harris, Stitcher and Heyl, 1982). 
In anaesthetized dogs, the fall in brain ACh caused by HC-3 has been 
associated with high voltage slow waves in the amygdala and neocortex, and 
inhibited EEG activation produced by electrical stimulation of the midbrain 
reticular formation, diffuse thalamic nuclei and posterior hypothalamus 
(Oren and Domino, 1968 ) . The hippocampal immobile rythmic slow activity of 
the rat is severely attenuated by intraventricular injection of HC-3; this 
activity is restored by subsequent systemic administration of choline 
chloride (Robinson and Green, 1980). 
In a study of the role of ACh in sleep, wakefulness and dreaming in 
cats, ivt injection of HC-3 facilitates slow wave sleep, but virtually 
abolishes paradoxical sleep (Hazra, 1970). HC-3 has also been investigated 
in the spinal cord. Iontophoretic application of HC-3 to Renshaw cells 
causes a dimunition in the number of spi kes, and a delay of the first spi ke 
of the Renshaw cell discharge after ventral root stimulation (Quastel and 
Curtis, 1965; Craig, Curtis and Lodge, 1977 ) . The change in the number of 
spikes is frequency dependent, but the increased latency is not, leading 
Craig et al. (1977) to propose both presynaptic and postsynaptic mechanisms 
of action in this preparation. 
Several synthetic analogues of HC-3 have been studied mainly as an 
attempt to elucidate structure-activity relationships. Schueler (1955 ) 
reported that HC-15, which is exactly half the HC-3 molecule, exhibited no 
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toxic activity in mice in doses up to 50 mg/kg. Bowman, Hemsworth and Rand 
(1967) demonstrated that HC-15 possesses a postjunctional, nondepolarizing 
block on neuromuscular transmission in the rat phrenic nerve-diaphragm 
preparation, although it is much less active than HC-3. Hemsworth (1971) 
reported that HC-15 causes both a prejunctional and postjunctional block of 
transmission in the cat sciatic nerve-tibial is muscle preparation; and 
furthermore demonstrated an anticholinesterase action. In none of these 
actions is HC-15 as potent as HC-3. 
Marshall and Long (1959) showed that the introduction of an ether or 
methylene linkage between the two phenyl rings of HC-3 produced only a 
minor decrease in potency. Subsequent studies have shown that the biphenyl 
moiety of HC-3 can be replaced by a hexamethylene chain (Powers, Kruger and 
Schueler, 1962), one phenyl ring (Thampi et al., 1966), or three phenyl 
rings (Gardiner and Sung, 1969) without appreciable loss of HC-3-like 
activity. Domer et al. (1980) synthesized a series of terphenyl compounds 
with HC-3-like activity, and found most of them to be as potent as their 
respective biphenyl analogues. 
DiAugstine and Haarstad (1970) studied several methyl analogues of HC-
3 and found hemicholinium-like activity, but less toxicity. Acetylation of 
HC-3 to produce the open ring acetyl secohemicholinium causes, in addition 
to the presynaptic blockade of choline transport, a more powerful direct 
inhibition of CAT, a systemic cholinomimetic activity, and a potentiation 
of catecholamine activity (Domino et al., 1973). Recently, 2-
bromoethylamine (mustard) derivatives of both HC-3 and HC-15 have been 
synthesized. The HC-3 bromomustard effected greater inhibition of sodium 
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dependent high affinity choline uptake in rat brain synaptosomes than HC-3 
(Smart , 1983), and is thus at present the most potent known synthetic 
inhibitor of this system. Synaptosomes treated to remove the drug showed 
maintained reduction in the Vmax of choline transport, and it has been 
suggested that HC-3 bromomustard forms a covalent bond with the transport 
mechanism, causing irreversible inhibition (Smart, 1983). 
In summary, the mechanism of action, and pharmacological properties of 
HC-3 have been discussed. The principal action of HC-3 is the inhibition 
of high affinity choline transport leading to diminished ACh synthesis; in 
addition, HC-3 is also a weak anticholinesterase and a postsynaptic 
neuromuscular blocker. 
Anticholinesterase Compounds 
The enzyme acetylcholinesterase (AChE) is found at cholinergic 
terminals throughout the central and peripheral nervous systems where it 
hydrolyses ACh to choline and acetate, terminating the action of ACh. 
Anticholinesterase agents inhibit AChE causing ACh to persist at 
cholinergic synapses, leading to excessive stimulation of cholinergic 
receptors . There are two classes of anticholinesterases, "reversible" 
(carbamate type) and "irreversible" (organophosphates). Physostigmine 
(eseri ne ), a carbamate anticholinesterase, is an alkaloid der i ved from the 
Calabar bean (the dried ripe seed of Physostigma venenosum Balfour), and 
early investigations of its pharamacological properties were conducted in 
mid-nineteenth century England (for historical review see Karczmar , 1970). 
In the 1950s a series of heterocyclic, aromatic and napthyl carbamates 
were synthesized as insecticides and found to be potent anticholinesterases 
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with a high degree of selective toxicity (Gysin, 1954 as cited in 
Taylor(1980)). Carbaryl was the prototype of this latter group. 
The first organophosphorous inhibitor synthesized was tetraethyl-
pyrophosphate (TEPP), by DeClermont in 1854 (cited in Karczmar, 1970). 
Lange, in 1935, recognized the potential of organophosphorous agents as 
insecticides and fungicides, and prior to the Second World War , several 
compounds (e.g., parathion) were synthesized for this purpose by Schrader 
(cited in Karczmar, 1970). Subsequently, more toxic "war gases'' such as 
tabun, soman and sarin were synthesized by Schrader's group under the 
direction of the German government (for review see Taylor, 1980). 
Investigators in Britain and America also searched for potentially toxic 
compounds, and diisopropylphosphorofluoridate (DFP) was synthesized by 
Mccombie and Saunders (1946). 
The active center of AChE contains a negative subsite called the 
anionic site and a catalytic "esteratic'' site. The anionic site binds to 
the quaternary nitrogen while the serine hydroxyl group of the esteratic 
site breaks the ACh ester bond and is itself acetylated. Regeneration 
occurs via spontaneous hydrolysis to yield acetate (for detailed account 
see Usdin, 1970). 
Physostigmine, neostigmine and other compounds with a methylcarbamate 
of a basically substituted simple phenol are hydrolysed by AChE in a 
reaction similar to that for ACh. The enzyme esteratic-site is, however, 
carbarnylated (Wilson , Hatch and Ginsberg, 1960), and in contrast to the 
acetylated enzyme (which regenerates within a few thousandth's of a second) 
spontaneous regeneration occurs much more slowly. This is because the 
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carbamylated enzyme i s far more stable and is thus unable to bind with ACh 
for the duration of carbamylation (Wilson and Harri son, 1961 ) . 
The organophosphates, like the carbamates, react at the esteratic 
site; the resultant phosphorylated enzyme being very stable. Compounds such 
as OFP are postulated to only react with the esteratic site, but compounds 
such as cholinylmethyl phosphono fluoridate are, in addition thought to 
react with the anionic site (Holmstedt, 1963; Usdin , 1970). Hydrolysis of 
the serine residue-phosphorous bond can occur at a very slow rate until a 
process called aging occurs. Aging occurs by dealkylation of the 
phosphorous atom to form a hydroxy group, thus stabilizing the enzyme-
inhibitor complex further (Jansz, Brons and Waringa, 1959; Harris et al., 
1966; Usdin, 1970). 
Inhibitors of AChE have profound pharmacological effects in the 
peripheral and central nervous systems. In the periphery the effects are 
dependent on interference of cholinergic transmission at autonomic and 
somatic neuromuscular effector sites. In the autonomic system, vagal 
potentiation by tabun causes bradycardia (Holmstedt , 1951 ) , although in 
dogs sarin and TEPP cause an increase in peripheral vascular resistance 
(DeBurgh and Wright, 1956), and in rats both sarin and DFP produce 
hypertension when given in sub-lethal doses (Dirnhuber and Cullumbine, 
1955). 
Duodenal activity is susceptible to anticholinesterase action; in 
dogs, both sarin and tabun increase tonus and rythmicity at doses producing 
no discernable effects on respiration or circulation (Krop and Kunkel , 
1954). Increasing doses of DFP administered to the isolated rabbit 
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duodenum produces spastic contraction (Shelley, 1955), the spleen of the 
dog is contracted by TEPP (Scott, 1957), and chronic administration of 
organophosphates produces gastric ulcers in var ious experimental animals 
(Holmstedt , 1959). Other autonomic, parasympathetic actions of 
anticholinesterases include increased salivation (Emmel in and Stromblad, 
1958), mi osis (Sanderson, 1957 ) , and bronchoconstr iction (Krop and Kun kel, 
1954). 
At the neuromuscular j unction, antichol i nesterases produce twitch 
potentiation, fasiculations, tetanic i nhibiton (Wedens ky i nhibition ) , and 
have an anti-curare action (Hobbiger, 1976). One preparation used 
extensive ly for studies of antichol i nesterases on neuromuscular 
transmission has been the rat isolated phrenic nerve-diaphragm preparation 
(Hobbiger, 1976 ) . Early studies showed that TEPP first enhances, then 
decreases single twitch response of the preparation (Burgen, Keele and 
Slome, 1949). Further studies showed that the response to TEPP, DFP and 
paraoxon was characterized by enhanced si ngle twitches, fasiculations and 
tetanic fade (Barnes and Duff, 1953). Barnes and Duff (1953 ) went on to 
measure AChE activity at various stages of paraoxon poisoning. They 
calculated that twitch potentiation starts when AChE is 60% inh i bi ted and 
the preparation returns to normal at 95% inhibition. 
Van der Meer and Meeter (1956a ) studied the effects of DFP on the rat 
phrenic nerve- diaphragm preparation. The contraction amplitude of the· 
muscle, when stimulated indirectly at 0.5 Hz was initiall y increased by 
DFP, then returned to pre-DFP values. Cholinesterase activity of the 
muscle was found to be 20% of control when single twitch potentiation 
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began, and was completely inhibited when contractions returned to pre-DFP 
values. Preparations not given nerve stimulation showed spontaneous 
contraction at 80% cholinesterase inhibition (Van der Meer and Meeter, 
1956a), these being postulated to occur via an antidromic reflex initiated 
by a presynaptic action of ACh (Randie and Straughan, 1964). 
Antagonism of tetanic contractions (tetanic inhibition ) of the rat 
phrenic nerve-diaphragm preparation by OFP has also been documented 
(Barstad, 1960). The preparations were stimulated for a period of 5 
seconds at either 60 Hz or 120 Hz, and following addition of DFP the 
tetanic contractions of the muscle were abolished within 11 minutes. 
Cholinesterase activity determinations showed that activity of 10-15% of 
normal is sufficient to sustain 60 Hz stimuli, and 15-20% activity is 
sufficient to sustain 120 Hz stimuli (Barstad, 1960). Using the same 
preparation, Fleischer et al. (1960) demonstrated tetanic inhibition at 80 
Hz and showed reversal of inhibition with TMB-4, an oxime reactivator. 
More recent work using paraoxon has shown that once tetanic fade starts to 
occur at a given percent reduction of cholinesterase activity, further 
small losses of AChE activity produce large reductions in tetanic response 
(Heffron and Hobbiger, 1979) . .!..!!. ~nerve-muscle preparations have also 
been used to study anticholinesterase activity. Procedures include the cat 
anterior tibialis and cat sciatic-gastrocnemius preparations ( for review 
see Werner and Kuperman, 1963); effects similar to that seen with the rat 
phrenic nerve diaphragm have been observed after close arterial injection 
(Hunt, 1947). 
Anticholinesterases also affect cholinergic components of the CNS. 
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The CNS pharmacology has been extensively reviewed by Karczmar (1967 ) and 
is briefly surrmarized below. OFP causes electrocortical arousal in monkeys 
and cats and lowers the sensory and electrical threshold of the reticular 
formation. Evidence also exists that anticholinesterases depress 
thalamocortical recruitment, produce an arousal pattern in the hippocampus, 
and depress cochlear responses to sound. The discharge of Renshaw cells 
are prolonged by anticholinesterases and the respiratory paralysis produced 
by DFP has been shown to be predominantly caused by a central component 
(for review see Holmstedt, 1959 and Karczmar, 1967) . 
The toxicological symptoms of anticholinesterase poisoning are 
manifested by the effects of excess ACh at peripheral and central 
muscarinic and nicotinic receptor sites. Symptoms caused by excessive 
muscarinic stimulation include miosis, blurred vision, rhinorrhea, broncho-
constriction, abdominal cramps, diarrhea, sweating, involuntary 
micturition, increased salivation and lacrimation, and bradycardia 
(Ho lmstedt, 1959). The neuromuscular junction and autonomic ganglia are 
susceptible to excessive nicotinic stimulation, which causes 
fasciculations, muscular twitching, and mild elevation of blood pressure. 
In higher doses the fasciculations become widespread, and muscular weakness 
and eventual failure occur (Holmstedt , 1959). The central manifestations 
of toxicity have been reviewed by Wills (1970 ); briefly, they are anxiety, 
dizziness, confusion, ataxia, coma and generalized convulsions. The EEG 
resembles the spiking seen in grand mal epilepsy. 
The drug of choice in treatment of anticholinesterase poisoning is 
atropine, which blocks muscarinic receptors. In addition, oxime 
21 
reactivators (e . g., pyridine-2-aldoxi me or 2-PAM), which displace 
organophosphates from the esteratic site of the enzyme to restore activity, 
may prove useful therapy. Reactivators cannot, however, displace the 
organophosphate once aging has occurred (for review see Wills , 1970; 
Taylor , 1980) , and 2-PAM does not cross the blood brain barrier {Ell in, 
1982 ) , thus limiting the therapeutic value of this oxime. 
Other approaches to treatment of organophosphate poisoning have 
included the use of carbamates. Pyridostigmine has been shown to reverse 
soman induced tetanic inhibition of the rat phrenic nerve-diaphragm 
preparation (French , Wetherell and White, 1979), and physostigmine has been 
demonstrated to have protective value against soman to xicity in rats 
{Harris, Stitcher and Heyl , 1980). The mechanism of actions of carbamates 
is not fully understood although Green (1983 ) has proposed that kinetic 
factors alone can account for the protective act ion. Pretreatment with 
several other compounds has been shown to increase the LD50 of 
organophosphates . Such compounds include 0-3- (trimethylammonio )-phenyl -
l,3,2-dioxaphosphorinane- 2-oxide iodide (TOPI) (Ashani et al . , 1983 ) , 
soman-simulator (Wolthius, Benschop and Berends, 1981), and sodium 
phenobarbital (Clement, 1983). Unfortunately none of these compou nds are 
of therapeutic value when administered subsequent to organophosphate 
exposure . 
Recognizing the potential of inhibitors of ACh synthesis as 
organophosphate antagonists, Harris, Stitcher and Heyl (1 982 ) gave 
intraventricular injections of HC-3 to rabbits, prior to intoxi cation wit h 
soman, and found that HC-3 increased the LD50 of soman several-fold . HC- 3 
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has also been shown to antagonize the tetanic inhibiton of the rat isolated 
phrenic nerve-diaphragm preparation following DFP in vitro or soman ..:!.!:!. vivo 
(Grieve and VanMeter, 1983). 
Investigations i nto possible antagonists of anticholinesterase 
poisoning, are hampered by the fact that anticholinesterases produce 
effects unrelated to inhibiton of the AChE enzyme. Organophosphates cause 
a variety of metabolic changes ( for review see Ell in , 1982), but most 
complications arise from direct effects on post synaptic receptors . 
Studies on neuromuscular transmission have shown that in the presence of 
DFP inhibited AChE, end plate current amplitude was restored despite 
continued 100% enzyme inhibition (Kuba and Albuquerque, 1973 ) . DFP 
administered to rabbits produces EEG seizures in the presence of previously 
inhibited AChE (VanMeter, Karczmar and Fiscus, 1978) . Both groups proposed 
that these observations were due to a direct action of OFP . Using patch · 
clamp techniques, Shaw, Akaike and Albuquerque (1983) have demonstrated a 
direct action of both pyridostigmine and physostigmine on the acetylcholine 
receptor-ionic channel complex . 
In addition to the prompt effects noted above, some organophosphates 
also produce delayed neurotoxicity . This effect is cha racterized by 
degeneration and demyelination of long fibers, and is postulated to occur 
because of inhibition of neurotoxic esterase (Johnson, 1974). Clinical 
symptoms i nclude weakening of distal muscles in limbs 6-14 days after 
exposure to organophosphates (for review of delayed neurotoxicity, see 
Abou - Donia, 1981). 
The biochemical, pharmacological and toxicological effects of 
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anticholinesterase agents described above are of interest because of the 
need for effective therapy following organophosphate poisoning. The rat 
isolated phrenic nerve-diaphragm preparation is a useful model of 
neuromuscular transmission, enabling study on the effects of 
organophosphates, and their potential antagonists. 
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METHODS AND MATERIALS 
Synthesis of a Tertiary Hemicholinium 
As tertiary hemicholiniums are not commercially available, one such 
compound was obtained by organic synthesis. The procedure used, which was 
based on the method of Long and Schueler (1954) as modified by DiAugustine 
and Haarstad (1970) , involved a three-stage synthesis beginning with a 
Friedel-Crafts addition of bromoacetylbromide onto bi phenyl. Bi phenyl (25 
g ,0.16 Moles) was dissolved in 150 ml of carbon disulfide in a 500 ml, 
three necked, round bottomed flask. The solution was cooled and 60 g of 
anhydrous aluminum chloride was slowly added while shaking. The mixture 
was then refluxed while slow addition of 80 g (0 .4 Moles) 
bromoacetylbromide caused liberation of HBr. After 2 hours, the reaction 
mixture was poured into a mixture of cracked ice, methanol and hydrochloric 
acid and stirred. The white product was collected on a filter paper and 
dried. A pure reaction product was obtained after two recrystallizations 
from tetrahydrofuran (THF) in 28% yield. 
To a solution of 6.0 g (0 .015 Moles) of the product (4,4 '-
dibromoacetyl biphenyl) dissolved in 30 ml of boiling THF, 3.0 g of (0 . 03 
Moles, 3.6 ml) of 4-methylpi peridine was added slowly. The mi xture was 
cooled, allowed to stand for 30 min, and the crystals which formed were 
collected on a filter paper, dissolved in absolute ethanol and precipitated 
through addition of anhydrous ether (Yield, 14-18%) . 
The product of this reaction (1.0 g) was then dissolved in water, and 
an excess (0.75 g) of sodium borohydride added. The free base of the 
tertiary hemicholinium crystallized out of solution , was filtered, dried 
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and recrystallized from THF, dried again and stored for use (Yield , 46%) . 
Structures of all products were confirmed by nuclear magnetic resonance 
spectroscopy (1H nmr(CDC1 3, TMS as internal standard) 0.8- 1.7 m, 4-
methylpiperidine, 2. 4 d, CH2 , 4.7 t, CH, 7.5 d, bi phenyl; ms 436.32 (calcd . 
436 .19 )) . 
Dissection 
To eliminate error due to differences between sexes and to ensure 
stable preparations, only young female rats, weighing between 150-250 g 
were used. Diaphragms from rats larger than 250 g were frequently found to 
be unstable. The animals (Sprague-Dawley or Sprague-Dawley and Norwegian 
crossbred rats) were killed by cerebral concussion fol l owed by 
exsanguination. The left thoracic wall was completely removed, the phrenic 
nerve was ligated and cut cranial to the ligature. The diaphragm was 
attached to a tissue holder with cotton thread, and another long section of 
cotton thread was tied to the central tendon. A fan-shaped slice of 
diaphragm with the phrenic nerve attached was removed from the animal, and 
placed in a 50 ml isolated tissue bath filled with Krebs 1 solution (see 
Appendix A ) at 37°c and aerated with 95% 02/ 5% co2 ( see Fig . 1) . The 
thread tied to the central tendon was attached to a Gould 33-03- 981 
isotonic transducer coupled to a Gould Brush 220 recorder . The phrenic 
nerve was placed in contact with platinum wire electrodes, and given 
cathodal stimulation, at a frequency of 1 Hz, with supramaximal voltage 
pulses of 1 msec duration delivered by a Grass SD9 stimulator. Tissues 
were allowed to equilibrate in the bathing solution for 20- 30 min to ensure 
stable responses to nerve stimul ation. 
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Fig.l. The rat phrenic nerve-diaphragm preparation 
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Data Recording and Analysis 
Data were recorded with an ink-writing, rectilinear Gould Brush 220 
recorder onto Gould Accuchart paper at a speed of 2S mm per minute. The 
paper was divided into primary squares of O.S cm and secondary squares of 
1.0 mm. In studies evaluating antagonism of the response of the 
preparation to HC-3, and antagonism of the response to HC-3 by choline, the 
parameter measured was the time required to reach SO% of control single 
twitch contraction amplitude (Ts0). As the response to 16 .0 µg/ml HC-3 was 
assumed to be maximal, in each preparation, the TSO obtained with 16.0 
µg/ml HC-3 was normalized to 1.00. Thus in each preparation , the Tso's 
obtained at all HC-3 doses were divided by the TSO obtai ned with 16.0 µg/ml 
HC-3 to yield ISO values. The mean and standard error of Isa values (a t 
each dose of HC-3) from different preparations were then computed . 
Antagonism Studies 
The known abi lity of HC-3 to deplete presynaptic cells of ACh makes 
this compound a potential physiological antagonist to organophosphates, 
which inhibit AChE and thus cause accumulation of ACh . In order to 
investigate depression of the preparation by organophosphates and 
physiological antagonism of this depression by HC-3, the following 
parameters were used: 1) amplitude of pretetanic single twitches, 2) 
amplitude of SO Hz tetanic contractions of S second duration, and 3) 
amplitude of post-tetanic single twitches as parameters . In DFP studies, 
SO Hz tetanic contraction amplitude was measured against control values to 
yield a% control value. In soman studies, the amplitude of contraction in 
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response to tetanic stimulation (T) was divided by the pretetanic single 
twitch amplitude to yield a T/S ratio, which is a measure of tetanic 
blockade. In both DFP and soman studies, the post-tetanic single twitch 
amplitude (P) was divided by pre-tetanic single twitch amplitude (S) to 
give a P/S ratio. The P/S ratio is a measure of post-tetanic potentiation 
or post-tetanic depression. 
Drug Applications--In Vivo 
Young adult female rats weighing 150-250 g were injected 
subcutaneously with 80, 160, or 320 µg/kg soman prior to experiments with 
the isolated phrenic nerve-diaphragm preparations, and the left phrenic 
nerve-diaphragms were removed as described previously 30 minutes post 
injection o·r on death. 
In experiments determintng the LD50 •s of HC-3 or the tertiary 
hemicholinium (tHC-3), rats were injected subcutaneously on the dorsal side 
of the abdomen. Animals which had not expired within 24 hours were 
assummed to be survivors. 
Drug Applications--In Vitro 
Drugs were added directly to the bathing solution ( for protocols, see 
Appendix B ) and were removed by complete evacuation of the tissue bath, 
and replacement with fresh Kreb's solution. 
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RESULTS 
HC-3 was administered in increasing doses until a SO% reduction in 
contraction amplitude (from 1.0 Hz stimulation) was observed. The mean 
dose at which this occurred, the minimum effective dose, was determined to 
be 30 µg/ml (n = lS preparations). 
In order to determine if the observed reduction in contraction 
amplitude was due to a presynaptic mechanism, HC- 3 (40 µg/ml) was 
administered to the preparation during nerve stimulation frequencies of 1.0 
Hz and 0.2 Hz. HC-3 caused a progressive blockade of the preparation at 
1.0 Hz, but this effect was not seen at 0.2 Hz (Fig. 2). 
HC-3 did not cause blockade of the rat diaphragm in a dose-dependent 
manner when initially applied. Repeated doses of 40 µg/ml HC-3 (followed 
after each dose by washing out of drug and full restoration of initial 
contraction ampiitude) caused the time required to reduce contraction 
amplitude 50% (Tso) to become successively shorter with each dose. 
Eventually, an equilibrium was reached where the maximum effect of HC-3 was 
seen at approximately a 16 µg/ml dose (i.e., doses higher than 16 µg/ml HC-
3 did not further reduce Ts0) . Doses of HC-3 lower than 16 µg/ml produced 
responses in a dose-dependent manner (Fig. 3). 
Choline chloride (8.0 µg/ml) applied to the preparation in the 
presence of HC-3 (4.rr, 6.0, 8.0 µg/ml) at TSO antagonized the decrease in 
contraction amplitude. The effects of HC-3 at doses higher than 8.0 µg/ml 
were not antagonized by choline chloride unless HC-3 was first washed out . 
Antagonism of HC-3 by choline was also demonstrated when choline was 
administered prior to HC-3 (Fig. 4). Pre-administration of choline 
Fig. 2. Effect of HC-3 (40 µg/ml) on single twitch contractions of rat diaphragm res ponse to 1.0 Hz 
(Trace I , II) and 0.2 Hz (Trace III) stimulation of the phrenic nerve 
I. HC-3 (40 µg/ml) causes a progressive reduction in amplitude of diaphragm contraction in 
response to 1.0 Hz stimulation; following wash-out of drug (w), contraction amplitude 
partially recovers. 
II. Recovery of contraction amplitude occurs after administration of choline chloride (Ch, 
8.0 µg/ml); this effect persists after wash-out of choline chloride (w). 
III. At a stimulation frequency of 0.2 Hz, HC-3 (40 µg/ml) fails to induce reduction in 
contraction amplitude. 
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Fig. 3. Relationship between HC-3 and 150 is dose-dependent 
Using a stimulation frequency of 1.0 Hz, HC-3 reduces 150 in a dose-dependent manner . The 
graph shows the mean + s.e.m. 
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Fig. 4. Choline ch loride (8.0 µg/ml) antagonizes HC-3 (12.0 µg/ml) depression of diaphragm 
contrac tion amplitude 
Upper trace: HC-3 (12.0 µg/ml) causes a 50% reduction of contraction amplitude after 3.7 min 
contact (T50 = 3.7 min) 
Lower trace: Cho line chloride {Ch, 8.0 µg/ml) induces recovery of contrac tion amplitude, 
still depressed after HC-3, and antagonizes the effects of HC-3 (12.0 µg/ml) by 
increasing r50 from 3.7 min to 4.8 min 
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chloride (8.0 µg/ml) increased the I50 compared to controls (Fig. 5) , but 
was only effective when the dose of HC- 3 was 4.0-8.0 µg/ml . 
DFP Studies 
Applications of 50 Hz stimulation to the phrenic nerve for 5 seconds 
produced tetanic contractions 2-3 times the amplitude of the preced ing 
single twitch. Immediately after cessation of 50 Hz stimulation, a post-
tetanic potentiation of 1.5-2 times the amplitude of pretetanic single 
twitches was also seen. DFP was applied first at a dose of 2.0 µg/ ml as a 
sensitivity test, and subsequently at a dose of 1.0 µg/ml in conjunction 
with an HC-3 or saline challenge. 
DFP (2.0 µg/ml) caused a reduction in post-tetanic potentiation after 
7 min contact, and both a depression of tetanic contraction amplitude and 
post- tetanic depression were seen after 14 min exposure (Fig. 6) . 
Preparations recovered 30 min after DFP was washed out (Fig . 6) . 
Subsequent administration of 1.0 µg/ml DFP, followed 1 min later by saline 
caused greater tetanic depression, and post-tetanic depression than did 2.0 
µg/ml DFP . However, if 1.0 µg/ml DFP was followed 1 min later by HC-3 
(40 . 0 µg/ml), tetanic depressi on was reduced, and post-tetanic depression 
was absent (Fig. 7). After DFP (1.0 µg/ml ) was wa shed out, amplitude of 
tetanic contractions in preparations given HC-3 recovered within 15 min , 
whereas recovery took 30 min in preparation given saline (Fig. 7) . 
Results from nine experiments demonstrated that HC-3 (40 µg/ml ) gave 
significant protection against DFP depression of 50 Hz tetanic contraction 
amplitude (Fig . 8), and also protected against DFP depression of post-
tetanic potentiation (Fig. 9). 
Fig. S. Effect of choline chloride on the dose-dependent relationship 
between HC-3 and ISO 
HC-3 causes a dose-dependent decrease in ISO ( shaded bars ) . 
Choline chloride (8.0 µg/ml) antagonized the effects of HC-3 (open 
bars) by signifi cantly increasing the ISO over control values; 
* graph shows mean + s .d. ( p < O.OS) . 
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Fig. 6. DFP (2.0 µg/ml) depresses 50 Hz tetanic contraction amplitude and post-tetanic potentiation 
Note depressed tetanic and post-tetanic contraction amplitudes after 14 min contact time 
(arrow) compared to contro ls (CT). Preparations A and B both recover after DFP wash-out 
(lower traces A and B). 
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Fig. 7. DFP (1 . 0 µg/ml) depression of 50 Hz contraction amplitude and post-tetanic potentiation is 
antagonized by HC-3 
Note difference in tetanic amplitude (arrows , a) and post-tetanic contraction amplitude 
(arrows, b) between preparations A and B. Recovery after DFP wash-out takes longer in 
preparation B (given saline,SAL). 
N. B. This figure is a continuation of Fig. 6. Preparations are the same as shown i n Fig. 6. 
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After 14 min exposure, 2. 0 µg/ml DFP (A) causes depression of 50 Hz tetanic contraction 
amplitude. After DFP wash-out, preparations recover. Subsequent exposure to 1.0 µg/ml DFP 
(B) followed by 40 . 0 µg/ml HC-3 causes significantly less depression of 50 Hz tetanic 
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Soman Studies 
Preparations taken from animals administered with soman were examined. 
Application of a stimulation frequency of 50 Hz for 5 seconds to the 
phrenic nerve showed that soman (160 µglkg and 320 µglkg) caused a 
reduction in tetanic contraction amplitude as compared with preparations 
taken from animals given saline (Figs. 10, 11 ) . Although admini stration of 
HC-3 (40 µglml) further reduced tetanic contraction amplit ude after 13 min 
contact, 5 min after HC-3 was washed out tetanic amplitude increased ove r 
pre-HC-3 amplitude and continued to increase over a 25 min period (Figs. 
10, 11). HC-3 caused post-tetanic depression during contact with the 
tissue, and, after HC-3 wash-out, post-tetanic contractions returned to 
pre-HC-3 amplitude. Administration of saline did not affect the 
preparations taken from rats receiving 160 µglkg soman (Fig. 10); but 
preparations from rats receiving 320 µgl kg soman recovered slowly in the 
presence of saline (Fig. 11). 
Soman (80 µglkg) failed to significantly alter the response of 
preparations to 50 Hz stimulation as compared to preparations from rats 
receiving saline injections. Neither TIS ratio (Fig. 12 ) nor PIS ratio 
(Fig. 13) significantly differed from control s , nor did HC- 3 (40.0 µglml ) . 
The T/S and PIS ratios of preparations ta ken from rats receiving 160 
µglkg soman, on the other hand, were depressed as compared to saline 
injected controls. Exposure to HC-3 (40.0 µgl ml ) for 6 min increased the 
TIS ratio (Fig. 14) but did not affect the PIS ratio (Fig. 15). After 13 
min contact, HC-3 caused a depression of TIS ratio (Fig. 14 ) and P/ S ratio 
(Fig. 15) compared with 6 min exposure. Once HC-3 was washed out, both the 
Fig. 10. HC-3 induces recovery of the tetanic contraction amplitude of isolated diaphragms taken from 
rats given soman (160 µg/kg s.c.) 
HC-3 (40.0 µg/ml) is administered to preparation A, and washed out 14 min later (A, upper 
trace). Note immediate recovery of tetanic contraction amplitude of preparation A (arrow) 
after exposure to HC-3; recovery is sustained after 25 min (A, lowe r trace). Saline does 
not significantly affect preparation (B, upper and lower traces). 
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Fig. 11. HC-3 increases rate of recovery of tetanic contraction amplitude in isolated diaphragms from 
rats given soman (320 µg/kg s .c . ) 
Preparation A is exposed to HC-3 (40.0 µg/ml) for 14 min (A, upper trace). Note immediate 
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Fig. 12. Soman (80 µg/kg s.c.) fails to alter T/S ratio of rat diaphragms 
placed ~ vitro 
TIS ratio of diaphragms from soman (80 µg/ kg) treated rats and 
control rats does not significantly differ. HC-3 (40 µg/ml) does 
not affect the T/S ratio of either group. The graph shows the 
mean + s.e.m. ~ - non- soman pretreatment (control ) . 
II , ~ - soman (80 µg/kg) pretreatment. 
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Fig. 13. Soman (80 µg/kg) fails to alter P/S ratio of rat diaphragms 
placed in vitro 
P/S ratio of diaphragms from soman (80 µg/kg) treated rats and 
control rats does not significantly differ. HC-3 (40 µg/ml) does 
not significantly affect the P/S ratio in control or soman 
groups. The graph shows the mean + s.e .m. ~ - non-soman 
pretreatment (control). • , • - soman (80 µg/kg) 
pretreatment. 
2.0 
en -Q. 
1.0 
w 
z 
...I 
< en -C") 
I 
(.) 
:c 
0 7 
:c en 
< 
3: 
14 20 
55 
80 µg/kg Soman 
--• ---• 40 µg/ml HC-3 n=8 
• • 80 µg/kg Soman n:4 
• • 40 µg/ml HC-3 n =8 
30 45 
TIME (MIN) 
Fig. 14. HC- 3 induces recovery from depression of T/S ratio in 
preparations from rats receiving soman (160 µg/kg) 
The T/S ratio of preparations ta ken from rats receiving 160 µg/kg 
soman s.c. is depressed compared to control preparations. The 
rate of recovery of T/S ratio in preparations given 40 µg/ ml HC- 3 
l!l vitro is greater than in preparations gi ven saline l!l vitro. 
The graph shows the mean + s.e.m. A - non-soman pretreatment 
(control). • , • - soman ( 160 µg/kg) pretreatment. 
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Fig . 15. HC-3 fails to induce recovery from depression of P/S ratio in 
preparations from rats given soman (160 µg/kg s.c.) 
The P/S ratio of preparations ta ken from rats given 160 µg/kg 
soman s . c . is depressed compared to controls. Neither HC-3 (40 
µg/ml) nor saline given_:!.!!. vitro induces significant recovery 
from this depression. The graph shows the mean + s.e .m. ~ -
non-soman pretreatment (cont rol). e, • - soman (160 
µg/kg) pretreatment. 
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TIS ratio and P/S ratios increased (Figs. 14, 15), but only the increase in 
TIS ratio was statistically significant (Table 1). Saline did not affect 
the T/S ratio or the P/S ratio in preparations taken from rats receiving 
160 µg/kg soman. 
Table 1. The effect of HC-3 on the increase in T/S ratio in preparations 
taken from rats receiving 160 µg/kg soman or 320 µg/k~ soman 
Treatment 
HC-3 (40 µg/ml) 
Saline (0.5 ml) 
*p 0.05. 
**p 0.01. 
Increase 
0.291 + 0.16** 
-0.084 + 0.12 
0 and 
g soman 
1.278 + 0.42* 
0.306 + 0.09 
The T/S and P/S ratios of preparations taken from rats receiving 320 
g/kg soman were further depressed. Exposure to HC-3 (40 .0 µg/ml) for 6 min 
increased the T/S ratio (Fig . 16), but not the P/S ratio (Fig . 17 ) . After 
13 min exposure to HC-3, the increase in T/S ratio was partially reversed 
(Fig. 16), and P/S ratio was decreased (Fig . 17). When HC-3 was washed 
out, the T/S ratio further increased (Fig. 16), and the depression of the 
P/S ratio was reversed (Fig. 17). Saline did not affect the T/S or P/S 
ratios (Figs. 16, 17) in preparations from rats receiving 320 µg/kg soman. 
Fig . 16. HC-3 increases rate of recovery from depression of T/S ratio in 
preparations from rats receiving soman (320 µg/kg) 
The T/S ratio of preparations taken from rats receiving 320 µg/kg 
soman s.c. is depressed compared to control preparations . The 
rate of recovery of T/S ratio in preparations given 40 µg/ml HC-3 
]..!! vitro is greater than in preparations given saline in vitro. 
The graph shows the mean + s.e.m. ~ - non-soman pretreatment 
(control). ~ , II - soman (320 µg/kg) pretreatment . 
4.0 
3.0 
en -I-
2.0 
1.0 
UJ 
z 
'.:j 
< en -(") 
I 
(.) 
J: 
0 7 
62 
14 20 30 
TIME (MIN) 
320 µg/kg Soman 
-------•40 µg/ml HC-3 n-:9 
------ee320 µg/kg Soman 
n·=11 
e e 40 µg/ml HC·3 n:S 
45 
Fig. 17. HC-3 fails to affect rate of recovery from depression of P/S 
ratio in preparations from rats given soman (320 µg/kg s.c.) 
The P/S ratio of preparations taken from rats given 320 µg/kg 
soman s.c. is depressed compared to co ntrols. Neither HC-3 (40 
µg/ml) nor saline given.:!...!!. vitro induces significant recovery 
from this depression. The graph shows the mean + s.e.m. A -
non-soman pretreatment ( contro 1). • , • - soman ( 320 
µg/kg) pretreatment. 
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HC-3 significantly increased the change in T/S ratio from the 
beginning of recording (0) to 5 min after HC-3 was washed out ( 20) in 
preparations from rats receiving either 160 µg/kg or 320 µg/kg soman (Table 
1 ) . 
LD50 studies were performed using rats to compare the toxicity of HC- 3 
and a tertiary hemicholinium (t-HC-3). Using a dose range of 20-60 mg /kg 
t-HC-3, the LD50 was estimated to lie between 35 and 40 mg /k g (Table 2) , 
when administered subcutaneously. 
Table 2. Relationship between mortality of rats and dose of tertiary 
hemicholinium (t-HC-3 ) following subcutaneous injection 
Dose o f t-H C- 3 
(mg/kg) 
20 
30 
40 
50 
60 
No. of animals 
(n) 
4 
6 
9 
10 
6 
% Mortality 
0 
0 
67 
100 
100 
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Using a dose range of 0.1-5.0 mg/kg HC-3, the LD50 was estimated to 
lie between 0.2 and 0.3 mg/kg (Table 3) when administered subcutaneousl y. 
Thus HC- 3 was found to be over a hundredfold more toxic than t - HC-3. 
Table 3. Relationship between mortality of rats and dose of hemicholinium-
3 (HC-3) following subcutaneous injection 
Dose of HC-3 No . 
(mg/kg) 
0.1 
0.2 
0.3 
0.5 
1. 0 
5.0 
of animals 
(n) 
4 
7 
6 
8 
10 
4 
% Mortality 
0 
14 
83 
100 
100 
100 
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DISCUSSION 
HC-3 causes a progressive reduction in contraction amplitude of the 
rat isolated phrenic nerve-diaphragm preparation at a stimulation frequency 
of 1.0 Hz. This action is thought to be due to HC-3 antagonism of high 
affinity choline uptake, thus reducing the amount of substrate available 
for ACh synthesis (Bowman , Hemsworth, and Rand, 1967 ) . The recovery of 
muscle contraction amplitude in the presence of choline chloride , and the 
failure of HC- 3 to induce neuromuscular blockade at 0.2 Hz (Fig. 2) 
provides further evidence that HC- 3 blockade of contraction amplitude at 
1.0 Hz is due to presynaptic mechanisms . 
The reason for successive doses of 40.0 µg/ml HC-3 causing the 
preparation to become more sensitive to HC-3 is unclear. HC- 3 is not 
thought to be an irreversible antagonist of choline transport (Yamamura and 
Snyder, 1973) , yet HC- 3 acts in a reversible manner only after a 
sensitization has occurred . 
Chang and Rand (1960) and Hemsworth (1971) both reported that choline 
was unable to reverse neuromuscular bl ockade in the rat diaphragm in the 
presence of HC- 3. These results (Fig . 3) , which show that HC- 3 can be 
antagonized by choline in the presence of HC-3, are in agreement with 
Takagi et al . (1970) , who reported that at a stimulation frequency of 0.7 
Hz, 10 µg/ml HC- 3 was antagonized by 10 µg/ml choli ne. The dose-response 
relationship obtained for HC-3 (Fig. 3) is a typical example of a drug -
receptor interaction, in which the binding of drug to receptor is 
reversible (Goldstein , Aronow, and Kalman , 1974 ) . Antagonism of HC- 3 by 
preadministered choline (Fig. 4) and the effect of preadministered choline 
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on the dose-relationship of HC-3 (Fig. 5) are a demonstration of properties 
of a competitive antagonist. Choline has been shown to be a competitive 
antagonist of HC-3 in whole animal to xicity (Schueler, 1955), at the cat 
superior cervical ganglion (Mcintosh, Birks, and Sastry, 1956) , and at the 
neuromuscular junction (Reitzel and Long, 1959a; Chang and Ra nd, 1960 ) ; 
thus the competitive antagonism of HC-3 by choline in the rat phrenic 
nerve-diaphragm is compatible with established data . 
Thus, because neuromuscular blockade is frequency dependent, and 
because HC-3 is competitively antagonized by choli ne, the slow, progressi ve 
antagonism of contraction amplitude of the rat phrenic nerve-diaphragm 
preparation by HC-3 at 1 Hz stimulation occurs due to the inhibition of 
presynaptic uptake of choline at the neuromuscular junction. The most 
likely site of action is the sodium dependent high affinity choline 
transport system (c .f. Yamamura and Snyder, 1973 ) . The blockade .of choline 
uptake results in diminished ACh synthesis, and thus a reduced pool of ACh 
available for release. 
Application of 50 Hz stimulation to the phrenic nerve caused tetani c 
contractions of the diaphragm (Fig. 6). Tetani c contractions occur because 
high frequency (50 Hz) stimulation of the phrenic nerve causes release of a 
large number of quanta of ACh which in turn stimulates the postsynaptic 
nicotinic receptors (Hobbiger, 1976). Administration of DFP causes single 
twitch contraction amplitude to increase, a phenomenon first observed by 
Van der Meer and Meeter (1956a) using 5.0 µg/ml DFP. In addition, Van der 
Meer and Meeter (1956a ) also observed a subsequent reversal of increased 
single twitch amplitude in the presence of DFP. 
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The increase of single twitch contraction amplitude is thought to be 
due to cholinesterase inhibition causing a persistence of ACh, which in 
turn causes presynaptic stimulation (positive feedback) and thus repetitive 
firing of muscle. The subsequent decrease in contraction amplitude is 
thought to be caused by almost complete cholinesterase inhibition, leading 
to enough over-stimulation of the postsynaptic receptors by ACh t hat 
depolarizing-desensitizing block occurs (Hobbiger , 1976). 
The reduction of tetanic contraction amplitude by DFP also occurs 
because of a depolarizing-desensitizing block induced by cholinesterase 
inhibition (Hobbiger, 1976). Cholinesterase determinations of rat 
diaphragms after DFP administration have revealed that tetanic blockade 
does not occur until cholinesterase activity is less than 15% of control 
(Barnes and Duff, 1953; Barstad, 1960; Hobbiger, 1976). 
Administration of 1.0 µg/ml DFP caused a more pronounced decrease in 
tetanic contraction amplitude than prior administration of 2. 0 µg/ml DFP 
(Figs. 6, 7, 8). This nondose-dependent action demonstrates that DFP is an 
irreversible antagonist of acetylcholinesterase, and that DFP (2 . 0 µg/ ml ) 
noncompetitively inhibits a certain fraction of the enzyme . 
HC-3 antagonizes DFP induced tetanic blockade (Fig. 7, 8) by 
antagon i sm of presynaptic choline transport. Deprived of the necessary 
substrate, ACh synthesis is reduced, and this in turn causes reduced ACh 
release (Bowman & Marshall, 1972 ) . DFP is antagonized when ACh release is 
reduced to an extent that it no l onger accumulates in the synaptic cleft. 
Post-tetanic potentiation is thought to primarily occur because of 
residual elevated calcium level s in presynaptic terminals (Mcintosh and 
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Collier, 1976), causing residual elevated release of ACh. DFP induces 
post-tetanic depression by the mechanism of tetanic blockade, i.e., 
cholinesterase inhibition; and HC-3 antagonized DFP by the competitive 
inhibition of presynaptic choline transport as described above . After 
administration of 1.0 µg/ml DFP, post-tetanic potentiation did not recover 
to pre-DFP (Fig. 9). The reason for this is unknown. 
Injection of 80 µg/kg soman s.c. into rats did not affect either 
amplitude of tetanic contractions (Fig . 12) or post-tetanic potentiation 
(Fig. 13), presumably because insufficient soman was distributed to the 
diaphragm to cause discernible blockade. However, many of the rats 
injected with 80 µg/kg soman (equivalent to 1 LD50 ) displayed signs of 
soman poisoning, showing that the neuromuscular junction was not the 
primary focus of soman toxicity. Injection of 160 µg/kg and 320 µg/kg 
soman did cause significant depression of tetani c contraction amplitude 
(Figs. 10, 11, 14, and 16) as measured by the T/S ratio, and also depressed 
post-tetanic potentiation (Figs. 10, 11, 15, and 17). Depressi on of 
tetanic contraction amplitude was observed by French, Wetherell, and White 
(1979) with 40 nM soman in vitro. In their study, 40 nM soman caused 
almost complete tetanic blockade, and cholineste rase activity was found to 
be 6% of control. The mechanism of action of soman in this study is 
presumed to be irreversible cholinesterase inhibition at the neuromuscular 
junction, as other studies have correlated soman-induced tetanic bloc kade. 
with cholinesterase inhibition in the rat diaphragm and other ·neuromuscular 
preparations (Dirnhuber and Green, 1978; French, Wetherell, and White, 
1979 ) . 
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However, the spontaneous recovery from tetanic blockade , seen after 
320 µg/kg soman, is in contrast with French, Wetherell, and White (1979) 
who found a permanent blockade with soman in vitro. Reasons for 
spontaneous recovery are not clear, although it is possible that soman 
action is not completely due to cholinesterase inhibition , and that any 
other effects (probably postsynaptic) are reversible . Another possibility 
is that the sensitivity of the ACh postsynaptic receptors are gradually 
adjusted to adapt to excessive ACh stimulation. However , these hypotheses 
are, as yet, untested. 
HC-3 antagonism of soman depression of T/S ratio is due to presynaptic 
antagonism of choline transport. HC-3 thus antagonizes soman by the same 
mechanism as it antagonized OFP. The mechanism by which HC- 3 causes a 
transitory depression of both T/S and P/S ratio while HC-3 is in contact 
with the diaphragm (Figs. 14, 15, 16, and 17) is unknown . The reason why 
HC-3 induced the recovery of P/S ratio depressed by DFP, but not P/S ratio 
depressed by soman is also unclear. 
The results of LD50 studies revealed that the tertiary hemicholinium 
(t- HC-3) was approximately one-hundred times less toxic than HC- 3, however, 
these two drugs are equipotent in minimum effective dose at the rat 
isolated phrenic nerve-diaphragm (Grieve and VanMeter, unpublished data) . 
Possible reasons for this discrepancy include differences in susceptibility 
to enzymatic degradation, or differences in protein binding; it shou ld be 
noted that nothing is at present kno wn about the biochemical pharmaco l ogy 
of t-HC-3. 
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In surrvnary, HC-3 causes a delayed and progressive inhibition of single 
twitch contractions of the rat isolated phrenic nerve-diaphragm 
preparation; and because this inhibition is frequency dependent and is 
antagonized by choline, HC-3 acts by antagonizing presynaptic choline 
transport and thus causes diminished ACh synthesis. By the same mechanism 
of action, HC-3 an tagonizes depression of tetanic contraction amplitude and 
depression of post-tetanic potentiation caused by organophosphorous 
cholinesterase inhibitors soman and DFP in the rat isolated phrenic nerve -
diaphragm preparation. 
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ABSTRACT 
The progressive reduction of muscle single twitch amplitude by HC- 3 
and the antagonism of this response by choline were examined in the rat 
isol ated phrenic nerve-diaphragm preparation. HC-3 antagonizes muscle 
contractions in response to 1.0 Hz but not 0.2 Hz phrenic nerve 
stimulation, indicating a frequency dependent action as reported in the 
literature. 
The effect of HC-3 to 1.0 Hz stimulation is antagonized by 
preadmi nistered and postadministered choline chloride (8 .0 µg/ml ) , at HC- 3 
doses of 4.0 , 6.0 , and 8 . 0 µg/ml; but choline fails to antagonize HC- 3 at 
HC-3 doses of 10.0, 12 . 0, and 16 . 0 µg/ml . As HC-3 action is frequency 
dependent and is antagonized by choline, it is proposed that HC- 3 acted by 
competitive inhibition of the presynaptic sodium dependent high affinity 
choline transport system. 
The response of the preparation to 50 Hz tetanic stimulation and the 
effect of DFP and soman on this response also was studied. DFP (2.0 µg/ml) 
in vitro causes depression of tetanic contraction amplitude and post-
tetanic depression, as does a subsequent administration of 1.0 µg/ml DFP in 
vitro. HC-3 (40.0 µg/ml) prevents tetanic blockade and post-tetanic 
depression in response to 1.0 µg/ml DFP. 
Soman was administered subcutaneously to rats at doses of 80.0, 160.0, 
and 320 . 0 µg/kg, and the phrenic nerve-diaphragms were removed for in vitro 
investigation. Preparations removed from rats given 80.0 µg/kg soman did 
not differ from controls given saline . In preparations from rats given 
160.0 µg/kg or 320.0 µg/kg soman, tetanic blockade and post -tetanic 
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depression were seen. HC-3 (40.0 µg/ml ), administered in vitro, 
significantly increased the rate of recovery of preparations from tetanic 
blockade, but did not significantly promote recovery of post-tetanic 
depression. 
It is proposed that DFP and soman caused tetanic blockade and post-
tetanic depression by cholinesterase inhibition, leading to ACh 
accumulation, and HC-3 antagonized DFP and soman by blockade of presynaptic 
choline transport. HC-3 was found to have a subcutaneous LD 50 of 
approximately 0.25 mg/kg in rats. A tertiary hemicholinium (t-HC-3 ) was 
synthesized as a potential antagonist of organophosphates. Th is compound 
was found to have a subcutaneous LD50 of approximately 37 mg /kg in rats. 
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APPENDIX A 
Composition of Krebs' solution (g/l itre ) 
NaCl 6.9 
KCl 0.35 
MgS04, FH 20 0.29 
KHl04 0.16 
Glucose 2.0 
NaHC0
3 2.1 
CaCl 
2 0.28 
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APPENDIX B 
1. Dose cycle for HC-3/Choline studies 
X µg/ml HC-3 until r 50 
WASH 
8.0 µg/ml Choline chloride until recovery 
X µg/ml HC-3 until r 50 
WASH 
8.0 µg/ml choline chloride until recovery 
WASH 
Doses of HC-3 were 4.0, 6.0, 8.0, 10.0 , 12.0 and 16 . 0 µg/ ml , 
given in that order. 
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2. Protocol for HC-3/DFP antagonism studies 
Time (min) Procedure 
- 02.00 50 Hz stimulation 
00.00 2. 0 µg/ ml DFP 
07. 00 50 Hz stimulation 
14.00 50 HZ stimulation 
15.00 WASH 
20.00 50 Hz stimulation 
30.00 50 Hz stimulation 
45 . 00 50 Hz stimulati on 
60 . 00 1.0 µg/ ml DFP 
67 . 00 50 Hz stimulation 
74.00 50 Hz stimulation 
75 . 00 WASH 
80.00 50 Hz stimulation 
90 . 00 50 Hz stimulation 
105 . 00 50 Hz stimulation 
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3. Protocol for HC-3/soman antagonism stud i es 
Time (min) Procedure 
00.00 50 Hz stimulation 
01.00 40.0 µg/ ml HC-3 or 0.5 ml sal i ne 
07.00 50 Hz stimulation 
14.00 50 Hz stimulation 
15.00 WASH 
20.00 50 Hz stimulation 
30.00 50 Hz stimul ation 
45.00 50 Hz stimulation 
